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To improve the efficiency of liposome-mediated DNA transfer as a tool for gene therapy or vaccinology, we have further
developed a new delivery system based on the modified immunopotentiating reconstituted influenza virus (IRIV). In this study,
we engineered a plasmid DNA vector expressing the mumps virus hemagglutinin or the fusion protein. The administration
of this DNA vaccine delivered by influenza virosomes, in combination with the mucosal adjuvant Escheriagen via the
intranasal route, was efficient for inducing an immune response, both mucosally and systemically, in mice. The production
of IgG2a mumps virus-specific antibodies and the secretion of interleukin 10 (IL-10) by antigen-specific T cells indicated that
not only Th1 but also Th2 responses were induced by this DNA vaccine formulation. These results suggest that cationic
virosomes in combination with Escheriagen may have great potential as an efficient delivery system for intranasal DNA
immunization and provide an immune barrier at the mucosal sites. © 2000 Academic PressKey Words: influenza virosome; mumps virus; DNA vaccine.INTRODUCTION
Mumps virus is a member of the Paramyxoviridae
family of the paramyxovirus genus. Parotitis is the most
common symptom of the disease, but the incidence of
meningitis following natural mumps infection has been
estimated to occur in about 10% of all cases (Furesz and
Contreras, 1990). Beginning in 1968, the widespread use
of the live attenuated mumps virus vaccine was followed
by a decrease in the incidence of mumps; however,
cases of infection after vaccination have still been oc-
curring (Boulianne et al., 1995; Brown et al., 1991; Forsey
et al., 1992; German et al., 1996; Jonville-Bera et al., 1996;
Nalin, 1992; Sugiura and Jamada, 1991). Lack of clinical
protection has been attributed to primary vaccine failure,
which occurs in persons who do not seroconvert after
vaccination or to a waning vaccine-induced immunity
(Briss et al., 1994).
In the present study we investigated the efficacy of a
mumps DNA vaccine intranasally delivered by virosomes
and administered to mice. Virosomes comprising cat-
ionic lipids and fusion active influenza hemagglutinin
protein appear to be a very efficient delivery system for
nucleic acid vaccines (Cryz and Glu¨ck, 1998; Waelti and
Glu¨ck, 1998). The use of DNA vaccines associated with
virosomes avoids the complex physicochemical prob-
lems associated with the use of adjuvants and may also
result in in vivo antigen presentation of the encoded
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 39 0577 233870. E-mail: cusi@unisi.it.
111epitopes in a manner similar to the presentation of the
epitope that would occur following natural infection. In
this investigation we combined the virosomal carrier
system with the mucosal adjuvant Escheriagen (E. coli
heat-labile toxin; Swiss Serum and Vaccine Institute,
Berne). Here we show that the priming of mice with
influenza virosomes and Escheriagen before vaccination
enhanced the humoral response. The results obtained
show that specific s-IgA antibodies are produced in the
mucosal layer of the respiratory tract and, in addition,
circulating IgG antibodies are also produced, indicating
that both systemic and distal mucosal responses are
induced in intranasally immunized mice.
RESULTS AND DISCUSSION
Plasmid immunogens and antigen expression
We engineered two plasmids, GC9 (MuV HN) and
GC23 (MuV F), to determine whether they could elicit
protective immunity against MuV. They were designed to
express the full-length, membrane-anchored MuV hem-
agglutinin and the fusion protein. Before testing them in
mice, they were tested in transfection assays in vitro.
Naked DNA, or DNA entrapped in influenza virosomes,
was able to express the antigens in Vero cells, as shown
by immunofluorescence tests (Fig. 1). The increased
expression of MuV proteins in vitro by transfection of
mixtures of DNA with virosomes as compared with trans-
fection of DNA alone was then confirmed by immunopre-
cipitation assay, as shown in Fig. 2.
0042-6822/00 $35.00
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112 CUSI ET AL.Influenza “priming” effect
Some groups of mice received the influenza priming
FIG. 1. Immunofluorescence localization of MuV HN or F using
specific anti-HN or anti-F MAbs (kindly provided by Prof. J. Wolinsky) on
Vero cells transfected with GC9/virosomes (A), GC23/virosomes (B), or
pcDNA3 (C). Magnification 3740.because we wanted to mimic the epidemiological situa-tion existing among humans. As shown in Table 1, the
“priming” of mice with influenza vaccine (Swiss Serum
and Vaccine Institute, Berne, Switzerland) and Escheria-
gen before immunization increased the humoral re-
sponse of either IgG and s-IgA in the nasal cavity, in-
creasing the antigen uptake and/or antigen presentation
(De Haan et al., 1996b; Douce et al., 1995; Verweij et al.,
998; Walker and Clements, 1993) (Table 1). Escheriagen
s known to be a very potent mucosal immunogen and
as also proved to be a strong adjuvant in humans
Glu¨ck et al., 1999). In the present study this priming,
dministered intranasally, significantly stimulated IgG re-
ponses and induced a local s-IgA response in mice. It is
FIG. 2. Immunoprecipitation and SDS–PAGE analysis of the MuV HN
and F antigens. Lanes 1 and 6 show mock-transfected cell extracts;
lanes 2 and 4, cellular extracts from Vero cells infected with GC9/
virosomes and GC23/virosomes; lanes 3 and 5, cellular extracts from
cells transfected with naked GC9 and naked GC23, respectively. Sam-
ples were tested with anti-MuV HN MAbs (1, 2, and 3) or with anti-MuV
F MAbs (4, 5, and 6). The molecular weight markers are shown on left
(Amersham Life Sciences).
TABLE 1
Immunological Response of Mice Immunized by Intranasal
Administration of MuV Vaccines at One Month after the Last
Immunization
Mice Serum IgG BAL IgA NW IgA
A (GC9) NEG NEG NEG
B (GC9)a 268 6 164 NEG NEG
C (GC9/virosome) 35 6 13 NEG NEG
D (GC9/virosome)a 1132 6 600 NEG 7 6 3
E (GC23) NEG NEG NEG
F (GC23)a 919 6 437 NEG NEG
G (GC23/virosome) 100 6 43 NEG NEG
(GC23/virosome)a 1393 6 358 NEG NEG
I (virosome alone) NEG NEG NEG
L (pcDNA) NEG NEG NEG
M (live MuV) 2270 6 1100 NEG 8 6 2
Note. Animals were administered with 5 mg of DNA/virosome or with
5 mg of naked DNA 6 Escheriagen. NEG, negative. The concentration
f the specific IgA (mg/mg of total IgA) in each NW sample was
ormalized to the total IgA concentration, and reported as means 6 SD.
he IgG values are given as antibody GMT 6 SD tested by ELISA.
a Group of mice that had received the influenza “priming.”
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113MUMPS DNA VACCINE DELIVERED BY VIROSOMESinteresting to note that, when priming was given with
Escheriagen alone or with influenza virosomes alone,
the adjuvant activity was suppressed. Moreover, Esche-
riagen did not show any adjuvant activity when admin-
istered with naked DNA (data not shown). Influenza HA
and Escheriagen appear to be effective in our system
only if they are administered together. The influenza
priming effect has also been observed using virosomes
as an antigen carrier system (Zurbriggen and Glu¨ck,
1999). It is possible that during the priming, Escheriagen
supports the action of HA on the virosomes that bind
macrophages and other immunocompetent cells through
sialic acid-containing receptors. The mechanism of the
influenza priming is not yet known. It is possible that the
synergic effect of the two factors promotes the produc-
tion of cytokines, which during the booster may have a
positive influence on the DNA immunization. Conse-
quently, the stimulated cells determine an enhanced im-
mune response whenever virosomes associated with
DNA plasmid are administered.
Humoral response to MuV antigens elicited by DNA
immunization
The efficacy of intranasal (i.n.) immunization with plas-
mid DNA encoding the HN was evaluated at the mucosal
site, with respect to the protocol of vaccination. Table 1
shows that i.n. immunization with DNA-virosomes after
priming resulted in a significant stimulation of the serum
IgG response with respect to the response induced by
i.n. immunization with naked DNA (P 5 0.03). It is gen-
rally assumed that the immunostimulating effect of li-
osomes primarily involves the uptake of liposome-as-
ociated antigen by cells of the mononuclear phagocytic
ystem (De Haan et al., 1996a; Lasic, 1998; McCluskie et
l., 1998; Wheeler et al., 1996). In our study, the influenza
A on the virosomes facilitates the targeting of plasmid
NA to antigen-processing and -presenting cells. The
ncreased uptake of DNA would result in an improved
xpression of the vaccine antigen (Templeton et al.,
997). Virosomes may also improve transfection effi-
iency by increasing the retention time and reducing the
ate of DNA degradation by extracellular nucleases
Dzau et al., 1996; Meyer et al., 1995). The MuV HN and
antigens are both capable of inducing specific anti-
uV antibodies. No cross-reaction was revealed be-
ween anti-MuV and anti-influenza antibodies as demon-
trated by immunoenzymatic assays. The influenza prim-
ng had a positive effect on the humoral immune
esponse of mice immunized with naked DNA (groups B
nd F), particularly with DNA-virosomes (groups D and
). These groups developed a response similar to that of
ice immunized with the live MuV (Urabe Am9 strain)
P 5 0.09).
This vaccine formulation also induced a neutralizingctivity. The sera from mice which had received priming snd were immunized with GC9 (MuV HN) developed a
eutralizing response (GMT 8.3 6 2.1) against the
umps virus, as did mice immunized with the live MuV
GMT 16). We did not find neutralizing antibodies in mice
mmunized with GC23. This result confirms other previ-
usly published data (Ko¨vamees et al., 1990; O¨rvell, 1984;
¨ rvell et al., 1997), which assess the presence of neu-
ralizing epitopes in the mumps virus HN (Cusi et al.,
ubmitted). The lack of an animal model suitable to show
he MuV pathogenesis has slackened the molecular
tudy of this virus. However, since the HN protein repre-
ents the major target to induce a protective immune
esponse to mumps virus (Houard et al., 1995), these
esults could be a step toward a genetically engineered
accine against mumps virus infections.
ucosal antibody response
By analyzing the mucosal immunity we found that,
mong the primed mice, only those immunized with GC9-
irosomes developed an amount of IgA in NW samples
omparable to the IgA level obtained in mice immunized
ith a high dose of live MuV (P . 0.05). Moreover, when
ice were immunized i.n. with a lower dose of live MuV
1000 TCID50/mouse), no IgA were detected in NW sam-
les. However, this response was short-lived. IgA anti-
odies were also detected in feces drawn 7–10 days
fter the last immunization, indicating that i.n. adminis-
ration of DNA also induces a mucosal immunity at the
nteric site (data not shown) (Asakura et al., 1997; Okada
t al., 1997). The presence of antibodies to the HN of
umps virus in the mucosa is very important, since they
epresent the barrier immunity and can prevent the bind-
ng of the virus to the specific receptor. It is unclear why
ice immunized with naked GC23 or GC23-virosomes
id not develop an IgA response; likely, the processing of
he two MuV antigens, HN and F, inside the cells is
ifferent; in fact, they induce a different Th response in
mmunized animals, which could be responsible for pro-
otion of IgA synthesis.
It is worth noting that IgA was revealed in the BALs
nly when mice had been immunized with GC9-viro-
omes and when the samples were drawn 2 weeks after
he last immunization (Table 2). It is possible that a
horter-interval period between immunizations is neces-
ary for inducing IgA in lungs, since the turnover is less
han 1 week for bronchial epithelial cells; moreover, it
as been suggested that alveolar macrophages sup-
ress immune responses in lung by inhibition of T-cell
roliferation and down-regulation of antigen-presenting
unctions of pulmonary dendritic cells (De Haan et al.,
996a). The results demonstrate that virosomes admin-
stered with DNA have the capacity not only to induce
gG response but also to stimulate a significant local
-IgA response in the secretory tract.
p
i
p
l
r
c
c
I
G
t
v
t
p
c
i
A
I
C
D
H
I
L
M
R
I
G
G
G
G
I
p
l
G
G
I
p
L
114 CUSI ET AL.Cell-mediated immune response in immunized mice
Th play an important role in eliciting both humoral and
cellular immune response (McDonnell and Askari, 1996;
Shearer and Clerici, 1997; Tighe et al., 1998); thus, T-cell
roliferation was examined. Four weeks after the last
mmunization, splenocytes from mice were examined for
roliferation in response to the specific antigen. Splenic
ymphocytes responded when 10 mg/ml of purified MuV
was used as antigen. As shown in Fig. 3, naked GC9 or
GC23 plasmids induced a Th proliferation response
higher than that of the negative control (P 5 0.02). How-
ever, when GC9 or GC23 plasmids were associated with
virosomes, Th cell proliferation levels were further en-
hanced. This can be explained by the fact that influenza
virosomes have been shown to be powerful stimulators
of T-cell proliferation (Saurwein-Teissl et al., 1998). Sim-
ilar results were also obtained regardless of whether
mice had been primed before vaccination. In general,
proliferation assays predominantly measure CD41 T-cell
esponses, a result supported by analyzing the pattern of
ytokines that the subsets of Th cells produced (Parron-
hi et al., 1991; Romagnani, 1991; Sher and Coffman,
1992). Antigen-specific cytokine production was not re-
vealed as well as the anti-MuV IgG isotyping because of
the low level of the specific IgG in mice of groups A, C,
E, and G. Table 3 summarizes representative cytokine
measurements of the responding animal groups (B, D, F,
H, and M) obtained from two separate experiments.
Mumps virus-stimulated cells from mice inoculated
with GC9-virosomes after the influenza priming induced
the production of IL-10, whereas the production of IL-2
was induced in cells taken from mice immunized with
naked GC23 and GC23-virosomes after priming. Cells
from mice immunized with live MuV induced mainly IL-10
(800 ng/ml) and, to a lesser extent, IL-2 (150 pg/ml). IFN-g
was not revealed in any sample, although this result
could be explained by the fact that the interferon system
TABLE 2
Immunological Response of Mice Immunized by Intranasal
dministration of MuV Vaccines at 12 Days after the Last
mmunization
Mice Serum IgG BAL IgA NW IgA
A (GC9) NEG NEG NEG
B (GC9)a 25 6 7 NEG NEG
(GC9/virosome) 30 6 5 8 6 7 10 6 4
(GC9/virosome)a 356 6 115 11 6 6 10 6 6
E (GC23) NEG NEG NEG
F (GC23)a 22 6 18 NEG NEG
G (GC23/virosome) 28 6 9 NEG NEG
(GC23/virosome)a 160 6 110 NEG NEG
(virosome alone) NEG NEG NEG
(pcDNA) NEG NEG NEG
(live MuV) 1585 6 566 20 6 10 NEG
a Group of mice that had received the influenza “priming.”could be suppressed in mumps virus-infected cells (Yo-kosawa et al., 1998; Hariya et al., 1999). Table 4 shows
the amount of specific IgG1/IgG2a immunoglobulins in
the sera of mice drawn after i.n. administration of MuV
vaccine or DNA-virosomes. The amount of IgG1 isotype
was predominant in mice immunized with GC9-viro-
somes, whereas the amount of IgG2a isotype was pre-
dominant in mice immunized with GC23-virosomes. This
result could be due to the fact that antibody isotype is
determined not only by the method of immunization but
also by the nature of both the antigen and the coimmu-
nized antigen (Cardoso et al., 1998). Intranasal immuni-
zation with live MuV induced IgG2a antibodies. Our re-
sults show that mucosal immunization with GC9-viro-
somes stimulates a Th2 response, since a higher
production of IgG1 and a significant level of IL-10 were
observed in immunized mice in addition to the presence
of IgA Abs, which are typical indicators of this response
(Wheeler et al., 1996), while the IgG isotyping (increase of
gG2a level) and IL-2 production in mice immunized with
C23-virosomes characterize a Th1 response. Many fac-
ors in vaccine design can influence dominant cellular
ersus humoral responses, such as the antigen dose,
he route of immunization, and the type of antigen. The
resence of virosomes as a new delivery system asso-
iated with different antigens could contribute to direct-
ng a response toward dominant cellular or humoral
TABLE 3
Antigen-Specific Cytokine Production from Splenic Cells of
esponding Groups of Mice following Influenza Priming and DNA
mmunization
Group IL-2 IFN-g IL-10
C9 0 0 200
C9-IRIV 0 0 50
C23 500 0 0
C23-IRIV 250 0 0
RIV 0 0 0
cDNA 0 0 0
ive MuV 150 0 900
Note. Values are given in pg/ml. Cells were stimulated with 10 mg/ml
of live MuV.
TABLE 4
Specific Anti-MuV IgG Isotyping
Group IgG IgG 1 IgG 2a
GC9 212 85.5 14
GC9-IRIV 323 105 9.5
C23 163 8 84
C23-IRIV 267 24.5 73.5
RIV 0 0 0
cDNA3 0 0 0
ive MuV 1862.5 235 1563Note. Values are given in ng/ml.
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115MUMPS DNA VACCINE DELIVERED BY VIROSOMESimmunity. The induction of mucosal IgA and neutralizing
antibodies by immunization with GC9-virosomes could
be very important to block the entry of MuV into the host.
However, a combination of the two vaccines containing
either the MuV HN or the MuV F proteins could represent
a good candidate to obtain both humoral and cellular
immune response.
A balanced Th1/Th2 cytokine profile, characterized by
a significantly higher IL-10 response and the predomi-
nance of IgG2a Abs, was observed in mice immunized
i.n. with the live MuV. In our study, HN and F proteins
appear to stimulate a different Th reponse; thus, the
presence of both of the antigens against the mumps
virus could be necessary for a vaccine capable of induc-
ing cellular and humoral immunity (Staats et al., 1994).
Safety of the vaccine
Little is known about how long the antigen is produced
after mucosal plasmid DNA administration. To address
this issue, lung tissue and lymphomonocytes were ex-
amined by PCR to reveal the presence of the plasmid.
Only 2% of the lymphocyte samples from the group of
mice immunized with DNA-virosomes revealed the pres-
ence of plasmid DNA 1 month after the last immuniza-
tion. No plasmid DNA was detected in lungs. It seems
that lymphomonocytes could be the vehicle for DNA-
virosomes. The persistence of the plasmid over a month
after immunization could be useful for an adequate ex-
pression of the recombinant vaccine protein. It would be
interesting to study the period of MuV genes expression
after immunization. Studies have shown liposome-formu-
lated DNA to be safe and nontoxic in animal models at
doses producing immunological responses (Caplen et
al., 1995; Porteous et al., 1997; Tsan et al., 1997). Influ-
enza virosomes were also shown to be nontoxic in mice;
moreover, this system has the advantage of using as
little as 5 mg of DNA to induce a good response and to
provide an immune barrier at the mucosal sites, since it
can be administered by the natural route of infection. It
should also be important to transfer the technology from
small animal models to nonhuman primates. The viro-
somes appear to be an effective tool for targeting and
gene delivery (Cusi and Glu¨ck, 2000), providing a novel
promising approach for the development of an effica-
cious human vaccine.
MATERIALS AND METHODS
Preparation of DNA plasmid:virosome complexes
The hemagglutinin (HN) and the fusion (F) genes of the
Urabe Am9 strain of the mumps virus were amplified by
RT-PCR (Cusi et al., 1995, 1996), digested with BamHI
and BglII, respectively, and ligated into the pcDNA3 ex-
pression vector (InVitrogen, San Diego, CA) to obtain the
recombinant plasmids GC9 (MuV-HN) and GC23 (MuV-F). Primers used for HN amplification were 59-AACG-
GATCCAGATGGAGCCCTCGAAA-39 and 59-AGGGATC-
CTTATCAAGTGATAGTCAATCT-39. Primers used for F am-
plification were 59-ACAGATCTGATCAGTAATCATGAA-39
and 59-ACAGATCTTCAGGAGTTTACCTT-39. The con-
structs were grown in DH5a cells and plasmid DNA was
purified by Qiagen EndoFree plasmid Kit (Qiagen, Chats-
worth, CA) as described by the manufacturer. Influenza
virosomes were prepared as described elsewhere
(Mengiardi et al., 1995; Waelti and Glu¨ck, 1998). IRIVs are
spherical, unilamellar vesicles which are prepared by a
mixture of natural and synthetic phospholipids contain-
ing egg yolk phosphatidylcholine, phosphatidyleth-
anolamine, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethyl-
ammonium methyl sulfate (DOTAP), and 10% envelope
phospholipids originating from influenza A/Singapore/
6/86 and influenza surface glycoproteins. Briefly, 1 ml of
DOTAP virosomes was added to 3.1 mg plasmid (1.3
mmol). Nonencapsulated plasmids were separated by
gel filtration on a High Load Superdex 200 column (Phar-
macia Fine Chemicals, Uppsala, Sweden). The column
was equilibrated with sterile PBS. The void volume frac-
tions containing the virosomes with encapsulated plas-
mids were eluted with PBS and collected.
Transfection of Vero cells in vitro
About 105 Vero cells were grown on coverslips at 37°C
nd infected with 0.3 mg of DNA-virosomes or trans-
fected with 1 mg of plasmid DNA using the Effectene
Transfection reagent (Qiagen) as described by the man-
ufacturer. After 2 days, mumps antigen expression was
analyzed by immunofluorescence. The cells were
washed twice with PBS, fixed with cold methanol/ace-
tone, and treated with either anti-MuV HN or anti-MuV F
MAbs (kindly provided by Prof. J. Wolinsky), followed by
FICT-conjugated goat anti-mouse immunoglobulin G (1/
100; Sigma, St. Louis, MO). The coverslips were mounted
on slides and examined using a Diaplan microscope
(Leitz, Wetzlar, Germany). Positive control (mumps virus-
infected cells) and negative control (mock-infected cells)
were included in each test.
Assessment of protein expression by RIPA
Vero cells (2 3 106) were plated onto a 35-mm tissue-
ulture dish, incubated for 1 h at 37°C, and transfected
s described above. At 24 h after transfection, the cells
ere washed with PBS three times, incubated in methi-
nine-free Dulbecco’s modified Eagle’s medium (DMEM;
ibco-BRL, Life Technologies, MI, Italy) for 1 h at 37°C,
nd radiolabeled for 4 h at 37°C in methionine-free
MEM containing 100 mCi [35S]methionine. The labeled
cells were washed with PBS and lysed with the lysis
buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.5%
Nonidet-P40 [NP-40]) at 4°C for 30 min. The cells debris
was pelleted by centrifugation at 15,000 g for 5 min at
4°C. The lysate was mixed with 30 ml of anti-MuV HN or
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116 CUSI ET AL.anti-MuV F MAbs and 30 ml 50% protein A–Sepharose
eads (Sigma) and incubated overnight at 4°C with ro-
ation. The immune complexes were washed with
NNTE buffer (50 mM Tris, pH 7.4, 5 mM EDTA, 0.5 M
aCl, 5% [w/v] sucrose, 1% [v/v] NP-40) and once with
IPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton,
.1% SDS, 1% deoxycholic acid). The precipitates were
esuspended in sample buffer and boiled for 5 min. The
ame protein amount (>10 mg) of each sample was then
resolved by electrophoresis on an SDS–polyacrylamide
gel. Following electrophoresis, the gel was fixed in iso-
propanol-acetic acid-dH2O, fluorographed with Amplify
eagent (Amersham Italia Srl, MI, Italy), dried, and ex-
osed on Kodak X-Omat film at 270°C.
mmunization of mice
Four-week-old female BALB/c mice (Charles River
reeding Laboratories, Wilmington, MA) were used.
ach experiment (n 5 6) was repeated three times to
nsure the reproducibility of results. Mice were anesthe-
ized with ketamine-xylazine and were immunized by i.n.
nstillation of 5 mg of DNA/mouse in a volume of 20 ml,
resulting in deposition of the inoculum throughout the
respiratory tract. Groups A–B and C–D were immunized
with naked GC9 plasmid and GC9-virosomes complex,
respectively; groups E–F and G–H were immunized with
naked GC23 plasmid and GC23-virosomes complex, re-
spectively. Booster immunizations were given 4 and 8
weeks after primary immunization. Groups B, D, F, and H
received an intranasal priming with influenza virus vac-
cine (20 ml containing 0.6 mg of HA and 40 ng of Esche-
riagen) 10 days before the first immunization. Control
groups consisted of mice administered virosomes alone
(group I), or pcDNA3-virosomes (group L), or 5 3 105
TCID50 of live mumps virus (Urabe Am9 strain) (group M).
or collection of bronchoalveolar lavages (BAL) and na-
al washes (NW), mice were terminated 2 weeks or 1
onth after the last immunization by cervical dislocation
nder anesthetization. Collection of BALs and NWs from
ice was performed as described elsewhere (Takao et
l., 1977).
LISA
IgG and IgA antibodies were measured by enzyme-
inked immunosorbent assay (ELISA). Since the concen-
ration of IgA in secretions is variable, the amount of
uV-specific IgA in NW samples was normalized to the
otal IgA concentration in each sample. Determination of
otal IgA was performed on flat-bottomed microtiter
lates coated with 100 ml of goat anti-mouse IgA (1
mg/ml; Southern Biotechnology Associates, Birmingham,
AL). Briefly, samples were diluted 1:50 and titrated in a
series of threefold dilutions. After incubation at 4°C over-
night, plates were washed three times and 100 ml of goat
orseradish peroxidase-labeled anti-mouse IgA (1/6000;
outhern Biotechnology Associates) was added. After mncubation at 37°C for 3 h, 3,39,5,59-tetramethylbenzidine
TMB; Sigma) was added and allowed to react at room
emperature for 30 min, and the reaction was stopped
ith 100 ml of 0.5 N H2SO4. Colorimetric conversion for
the substrate was measured in a microplate spectropho-
tometer at 450 nm (Behring).
For the determination of mumps virus-specific IgG and
IgA antibodies, purified virions of mumps virus were
diluted in coating buffer (0.05 M NaHCO3/Na2CO3, pH
.6) to 1 mg of proteins per ml, and dispensed to a
96-well plate at 100 ml/well. After allowing them to ab-
sorb overnight at 4°C, the wells were washed with PBS–
0.05% Brij 35 and blocked for preventing nonspecific
binding by incubation with 5% heat-inactivated fetal calf
serum (FCS) in PBS–Brij 35 for 2 h at room temperature.
A 100-ml aliquot of samples was diluted twofold in the
plate and allowed to react for 1 h at 37°C. The plate was
then washed and 100 ml of goat horseradish peroxidase-
labeled anti-mouse IGg (g) antiserum (1/8000; Bio-Rad,
ichmond, CA) for IgG ELISA or goat anti-mouse IgA (a)
ntiserum (1/6000; Southern Biotechnology Associates)
or IgA ELISA was added and the plate was incubated for
h at 37°C. After washing, the substrate was added and
llowed to react at room temperature for 30 min. Color-
metric conversion for the substrate was measured in a
icroplate spectrophotometer at 450 nm (Behring). IgG
iters of samples were calculated from endpoint dilutions
howing an optical density at least twice the value of the
ackground represented by a pool of negative control
era. The concentration of total and MuV-specific IgA
as calculated against a standard curve of mouse my-
loma IgA (Cappel Laboratories, Cochranville, PA) deter-
ined on the same plate. Results were expressed as
21
FIG. 3. T-cell proliferation responses following DNA immunization
against MuV. Spleens were collected from mice immunized with GC9
(groups A–D), GC23 (groups E–H), or live MuV (Urabe Am9 strain)
(group M), and their lymphocytes were isolated and tested for T-cell
proliferation. Groups I and L represent the negative control of mice
immunized with influenza virosomes and pcDNA3, respectively.icrograms of MuV-specific IgA mg of total IgA.
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117MUMPS DNA VACCINE DELIVERED BY VIROSOMESNeutralization assay
Virus neutralization was carried out on Vero cells in a
96-well microplate (O¨rvell et al., 1997). Briefly, serial two-
fold dilutions of immunized mice serum were added to
an equal volume of mumps virus (wild type MuV strain,
isolated and sequenced in the laboratory of the Micro-
biology Section, University of Siena) containing 100
TCID50 in 50 ml and incubated for 90 min at 37°C. A 50-ml
ample of cells (106/ml) was suspended in MEM with 5%
CS and added to each well. Five days after incubation
t 37°C, the cultures were examined microscopically for
he presence of the cytophatic effect.
ytokine assay
Splenocytes were drawn from immunized mice and
ymphocytes were collected by Ficoll–Hypaque (Pharma-
ia) gradient. About 100 ml of 2 3 106 unfractionated cells
er ml in a complete RPMI 1640 plus 10% FCS were
ultured in a total volume of 200 ml with 10 mg/ml of
urified mumps virus or phytohemagglutinin (PHA, 5 mg/
l; Sigma) in a 96-well flat-bottomed plate. Control wells
eceived cell suspension only. After 24 h in culture, cell-
ree supernatants were harvested for the presence of
L-2 and, after 48 h, for the presence of IFN-g and IL-10.
amples were stored at 280°C. Briefly, microtiter plates
ere coated overnight at 4°C with 100 ml of anticytokine
capture MAb (Pharmingen, San Diego, CA) at 1 mg/ml.
he plates were washed twice with PBS–Tween and
locked with 100 ml of 10% FCS in PBS per well per 2 h
at room temperature. The plates were then washed twice
and incubated with duplicates of serially diluted samples
and standards (Sigma) overnight at 4°C. Then 100 ml of
the biotinylated anticytokines (Pharmingen) MAb at 1
mg/ml was added to each well and the mixture was
incubated at room temperature for 1 h. The plates were
then washed three times, 100 ml of streptavidin-peroxi-
ase (1/1000; Sigma) was added, and the mixture was
ncubated at room temperature for 30 min. Following
ultiple final washings, the color was developed with
MB (Sigma) and stopped with 100 ml of 0.5 N H2SO4,
and the absorbance at 405 nm was measured with an
ELISA plate reader. The concentration of cytokines in
samples was determined according to the standard
curve.
Lymphocyte proliferation assay
To determine whether MuV lymphoproliferative re-
sponses were induced in immunized animals, their
spleens were removed 4 weeks after the last immuniza-
tion to make a single cell suspension. A 100-ml sample of
plenocytes (2 3 106/ml) in complete RPMI 1640 was
dded to each well in 96-well flat-bottomed plates. Stim-
lated cells received purified MuV at a concentration of
0 mg/ml; transferrin served as a negative control (120mg/ml; Sigma) and PHA (5 mg/ml; Sigma) as a positiveontrol. Control wells received cells only. The cells in the
ell were cultured in 200 ml of medium. After 4 days in
culture, the cells were pulsed with [3H]thymidine (1 mCi/
well) for 18 h and harvested with FilterMate (Packard,
Downers Grove, IL) and the incorporated radioactivity
was determined by TopCount (Packard). The stimulation
index was calculated as the mean cpm of the stimulated
wells divided by the mean cpm of the control wells.
PCR
PCR was performed on DNA extracted from the lym-
phocytes and the lung tissue (2 mg) of immunized mice
by using the QIAamp tissue Kit (Qiagen), as described by
the manufacturer. Each sample was subjected to 40
cycles at 94°C for 1 min, 56°C for 40 s, and 72°C for 90 s.
The primers used to detect GC9 were the sense 59-TCCA-
ATGGAGCCCTCGAAA-39 and the antisense 59-TTAT-
CAAGTGATAGTCAATCT-39. The primers used to detect
GC23 were the sense 59-CCGCGATCAGTAATCATGAA-39
and the antisense 59-GCCGCTCAGGAGTTTACCTT-39.
tatistical analysis
Antibody titers are presented as geometric means 6
D. The Mann–Whitney rank sum test was used to ana-
yze changes in the level of total and specific IgG and
gA. P , 0.05 was considered significant.
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